Status:
TERMINATED
Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Immunov
URC-CIC Paris Descartes Necker Cochin
Conditions:
Autoimmune Diseases
Inflammatory Disorder
Eligibility:
All Genders
18+ years
Brief Summary
Vaccination against the new coronavirus (SARS-CoV-2) was extended to patients at risk of severe forms of Covid-19, including in particular patients with autoimmune and inflammatory diseases treated by...
Eligibility Criteria
Inclusion
- Group 1 :
- Patient over 18 years old,
- Patient informed and not opposed to participate
- Patient followed for an autoimmune or inflammatory disease (vasculitis, systemic lupus, systemic sclerosis, non-infectious uveitis)
- Treatment with immunosuppressant and / or immunomodulator
- Group 2 :
- Patient over 18 years old,
- Patient informed and not opposed to participate
- Patient not followed for an autoimmune or inflammatory disease (vasculitis, systemic lupus, systemic sclerosis, non-infectious uveitis)
- Absence of treatment with immunosuppressant and / or immunomodulator
Exclusion
- Contraindication to vaccination
- Progressive cancer
- Pregnant or breastfeeding woman
- Current infection less than 3 weeks old
- Weight less than 40 kg
- Patient under tutor- or curator-ship
- Patient without health insurance
Key Trial Info
Start Date :
May 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 13 2022
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT04870411
Start Date
May 12 2021
End Date
March 13 2022
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Internal medicine Service - Cochin Hospital
Paris, France, 75014